NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Reviewer access | Sign OutHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE152254 Query DataSets for GSE152254
Status Public on Oct 01, 2020
Title A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Alterations to the androgen receptor (AR) signalling axis and cellular metabolism are hallmarks of prostate cancer. This study provides insight into both hallmarks by uncovering a novel link between AR and the pentose phosphate pathway (PPP). Specifically, we identify 6-phosphogluoconate dehydrogenase (6PGD) as an AR-regulated gene that is upregulated in prostate cancer. Knockdown of 6PGD impairs growth and elicits death of prostate cancer cells, at least in part due to increased oxidative stress. We investigated the therapeutic potential of targeting 6PGD using 2 specific inhibitors, physcion and S3. Both compounds exhibited substantial anti-cancer activity in multiple models of prostate cancer, including aggressive models of castration-resistant disease that are resistant to contemporary therapy. Mechanistically, 6PGD inhibits AMPK signalling, resulting in increased activity of the anabolic pathways regulated by ACC1 and mTOR. Importantly, the ability of S3 to inhibit prostate cancer growth was recapitulated in prospectively collected tumours using a patient-derived explant (PDE) system. Interestingly, inhibition of 6PGD decreases the expression and activity of AR in both cell lines and PDEs, revealing a novel positive feedback loop between these factors. Supporting the biological relevance of this feedback loop, co-targeting of AR and 6PGD was more effective than targeting either factor alone. Collectively, this work provides new insight into the dysregulated metabolism of prostate cancer and provides impetus for further investigation of co-targeting AR and the PPP as a novel therapeutic strategy.
 
Overall design RNA-seq following Enzalutamide treatment or AR knockdown in LNCaP cells.
 
Contributor(s) Butler LM, Selth LA, Gillis JL, Lynn D, Moldovan M
Citation(s) 34382934
Submission date Jun 11, 2020
Last update date Aug 15, 2021
Contact name Luke Selth
E-mail(s) luke.selth@flinders.edu.au
Organization name Flinders University
Department College of Medicine and Public Health
Street address Flinders Drive
City Bedford Park
State/province SA
ZIP/Postal code 5042
Country Australia
 
Platforms (1)
GPL18573 Illumina NextSeq 500 (Homo sapiens)
Samples (16)
GSM4610258 siCon_replicate1
GSM4610259 siCon_replicate2
GSM4610260 siCon_replicate3
Relations
BioProject PRJNA638813
SRA SRP266899

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE152254_All_data_cpm.txt.gz 1.3 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap